131 related articles for article (PubMed ID: 10633218)
1. Circulating insulin inhibits glucagon secretion induced by arginine in type 1 diabetes.
Oskarsson PR; Lins PE; Ahré B; Adamson UC
Eur J Endocrinol; 2000 Jan; 142(1):30-4. PubMed ID: 10633218
[TBL] [Abstract][Full Text] [Related]
2. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of circulating insulin on glucagon secretion during hypoglycemia in type I diabetic patients.
Liu DT; Adamson UC; Lins PE; Kollind ME; Moberg EA; Andréasson K
Diabetes Care; 1992 Jan; 15(1):59-65. PubMed ID: 1346593
[TBL] [Abstract][Full Text] [Related]
4. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
5. Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.
Israelian Z; Gosmanov NR; Szoke E; Schorr M; Bokhari S; Cryer PE; Gerich JE; Meyer C
Diabetes Care; 2005 Nov; 28(11):2691-6. PubMed ID: 16249541
[TBL] [Abstract][Full Text] [Related]
6. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
7. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
Kruszynska YT; Goulas S; Wollen N; McIntyre N
J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
[TBL] [Abstract][Full Text] [Related]
8. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.
Hamaguchi T; Fukushima H; Uehara M; Wada S; Shirotani T; Kishikawa H; Ichinose K; Yamaguchi K; Shichiri M
Diabetologia; 1991 Nov; 34(11):801-6. PubMed ID: 1769438
[TBL] [Abstract][Full Text] [Related]
9. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans.
Gosmanov NR; Szoke E; Israelian Z; Smith T; Cryer PE; Gerich JE; Meyer C
Diabetes Care; 2005 May; 28(5):1124-31. PubMed ID: 15855577
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of exaggerated glucagon response to arginine in diabetes mellitus.
Kawamori R; Shichiri M; Kikuchi M; Yamasaki Y; Abe H
Diabetes Res Clin Pract; 1985 Oct; 1(3):131-7. PubMed ID: 3915260
[TBL] [Abstract][Full Text] [Related]
11. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.
Banarer S; McGregor VP; Cryer PE
Diabetes; 2002 Apr; 51(4):958-65. PubMed ID: 11916913
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
13. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
Oskarsson PR; Lins PE; Backman L; Adamson UC
Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
[TBL] [Abstract][Full Text] [Related]
14. In vivo inhibition of glucagon secretion by paracrine beta cell activity in man.
Asplin CM; Paquette TL; Palmer JP
J Clin Invest; 1981 Jul; 68(1):314-8. PubMed ID: 7019246
[TBL] [Abstract][Full Text] [Related]
15. A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man.
Liu D; Moberg E; Kollind M; Lins PE; Adamson U
J Clin Endocrinol Metab; 1991 Nov; 73(5):1123-8. PubMed ID: 1682339
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Kielgast U; Asmar M; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2010 May; 95(5):2492-6. PubMed ID: 20207828
[TBL] [Abstract][Full Text] [Related]
17. Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.
Luyckx AS; Mendoza E; Lefebvre PJ
Diabetologia; 1981 Oct; 21(4):376-82. PubMed ID: 7026333
[TBL] [Abstract][Full Text] [Related]
18. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
Orskov L; Alberti KG; Mengel A; Møller N; Pedersen O; Rasmussen O; Seefeldt T; Schmitz O
Diabetologia; 1991 Jul; 34(7):521-6. PubMed ID: 1916058
[TBL] [Abstract][Full Text] [Related]
19. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
